1-3 of 3
Theresa Proia
Close
Sort by
Journal Articles

Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas

Scott Boiko, Theresa Proia, Maryann San Martin, Gareth P. Gregory, Michelle Min Wu, Neeraj Aryal, Maureen Hattersley, Wenlin Shao, Jamal C. Saeh, Stephen E. Fawell, Ricky W. Johnstone, Lisa Drew, Justin Cidado
Journal: Blood
Blood (2021) 137 (21): 2947–2957.
https://doi.org/10.1182/blood.2020008528
Published: 2021
Includes: Supplemental data
Journal Articles

Combination of AZD4573, a Selective CDK9 Inhibitor, with Other Cell Death Inducing Agents Can Overcome De Novo Venetoclax Resistance in Preclinical Hematologic Tumor Models

Justin Cidado, PhD, Scott Boiko, MS, Theresa Proia, PhD, Haley Woods, MS, Omid Tavana, PhD, Maryann San Martin, MS, Adriana E. Tron, PhD, Wenlin Shao, PhD, Lisa Drew, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3946.
https://doi.org/10.1182/blood-2018-99-113423
Published: 2018
Journal Articles

Combined Inhibition of mTOR and BTK Signaling Is Required for Optimal Long Term Growth Inhibition in DLBCL Models

Wolfram Brugger, MD, Maureen Hattersley, PhD, Alexandra Bussey, PhD, Corinne Reimer, PhD, Adriana E. Tron, PhD, Anna Staniszewska, PhD, Oona Delpuech, PhD, Larissa Carnevalli, PhD, Cecile M. Krejsa, PhD, Michele Mayo, PhD, Lynne Neveras, PhD, Maryann San Martin, PhD, Abla Rideout, PhD, Theresa Proia, PhD, Brandon Willis, PhD, J. Elizabeth Pease, PhD, Ahmed Hamdy, MD, Sabina C. Cosulich, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4113.
https://doi.org/10.1182/blood.V130.Suppl_1.4113.4113
Published: 2017